Aspiration coronary thrombectomy for acute myocardial infarction increases myocardial salvage: single center randomized study

Catheter Cardiovasc Interv. 2011 Oct 1;78(4):523-31. doi: 10.1002/ccd.22933. Epub 2011 Jun 6.

Abstract

Objectives: The aim of the study was to assess if aspiration thrombectomy in high risk patients with STEMI and angiographic evidence of thrombus may improve myocardial salvage.

Background: It is unclear if thrombus aspiration before percutaneous intervention (PCI) improves myocardial salvage.

Methods: The trial was a prospective randomized study. The inclusion criteria were: first STEMI within 12 hr from symptoms onset, culprit lesion in left anterior descending or right coronary artery, culprit artery TIMI flow ≤ 2 and angiographic evidence of thrombus. The primary endpoint was myocardial salvage index (MSI) as assessed by (99m) Tc-sestamibi SPECT imaging.

Results: We randomized 137 patients (98 male, mean age 64.1 ± 12.5 years) either to aspiration thrombectomy followed by standard PCI with stent implantation (n = 67) or to standard primary PCI (n = 70). Index perfusion defect was similar in both study groups: 34.2% ± 13.1% in thrombectomy group versus 37.1% ± 12.0% in primary PCI group (P = 0.2). MSI was larger in aspiration thrombectomy group than in control patients [25.4% (IQR 13.5-44) vs. 18.5% (IQR 7.7-30.3) respectively, P = 0.02]. The final infarct size was smaller in patients treated with aspiration thrombectomy (23.1% ± 13.3% vs. 28.9% ± 10.2% in the control group, P = 0.002).

Conclusions: Aspiration thrombectomy improves myocardial salvage in high risk STEMI patients with angiographic evidence of thrombus.

Trial registration: ClinicalTrials.gov NCT00675480.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Aged
  • Angioplasty, Balloon, Coronary* / adverse effects
  • Angioplasty, Balloon, Coronary* / instrumentation
  • Angioplasty, Balloon, Coronary* / mortality
  • Antibodies, Monoclonal / therapeutic use
  • Chi-Square Distribution
  • Combined Modality Therapy
  • Coronary Angiography
  • Coronary Circulation
  • Coronary Thrombosis / complications
  • Coronary Thrombosis / diagnosis
  • Coronary Thrombosis / mortality
  • Coronary Thrombosis / physiopathology
  • Coronary Thrombosis / therapy*
  • Electrocardiography
  • Female
  • Hospital Mortality
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Myocardial Perfusion Imaging / methods
  • Myocardium / pathology
  • Platelet Aggregation Inhibitors / therapeutic use
  • Poland
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals
  • Risk Assessment
  • Risk Factors
  • Stents
  • Suction
  • Technetium Tc 99m Sestamibi
  • Thrombectomy / adverse effects
  • Thrombectomy / methods*
  • Thrombectomy / mortality
  • Tomography, Emission-Computed, Single-Photon
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
  • Abciximab

Associated data

  • ClinicalTrials.gov/NCT00675480